Labcorp

Result Status: Final

Patient Name:		Account Number:	
Patient Phone:		Account Name:	
Date of Birth (Age):			
Sex:			
Referring Dr (NPI #):		Collection Date/Time:	
Patient ID:		Received Date/Time:	
Specimen ID:		Reported Date/Time:	

General Comments and Additional Information

Test(s) 164083-SARS-CoV-2 Semi-Quant IgG Ab; 164084-
SARS-CoV-2 Spike Ab Interp
has not been FDA cleared or approved. This test has
been authorized by FDA under an Emergency Use Authorization
(EUA). This test is only authorized for the duration of the
declaration that circumstances exist justifying the authorization
of emergency use of in vitro diagnostics for detection and/or
diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21
U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or
revoked sooner. This test has been authorized only for detecting
the presence of antibodies against SARS-CoV-2, not for any other
viruses or pathogens.

Fasting: No **Total Vol:** **Source:**

Result Name	Flag	Result	Range/Units	Status	Lab
164055 SARS-CoV-2 Antibody, IgG					
SARS-CoV-2 Semi-Quant IgG Ab		<13.0	Neg <13.0 / AU/mL	Final	01
SARS-CoV-2 Spike Ab Interp		Negative		Final	01

This sample does not contain detectable antibodies against the
SARS-CoV-2 spike protein, including the receptor binding domain
(RBD).
This assay was performed using DiaSorin Liaison(R) SARS-CoV-2
Trimeric S IgG assay.